1
Table S1 Diagnostic and prognostic value of circulating miRs in patients with different cancer entities
Number
Tumour
Cancer type
of
microRNAs
Diagnosis Prognosis Source
Time Point
Ref.
Stages
patients
miR-20a, miR-24, miR-25, miR-145, miRPre400
152, miR-199-5p, miR-221, miR-222,
X
Serum
I-IV
1
III-IV
2
I-IIIa
3
I-IV
4
III-IV
5
I-IV
6
operative
miR-223, miR-320,
260
miR-125b
243
miR-486, miR-30d, miR-1, miR-499
X
X
Serum
X
Serum
Inoperable
after
therapy
Lung cancer
Pre193
miR-125b
X
Serum
operative
Pre-
191
miR-16
X
Serum
operative
184
miR-93, miR-100, miR-134, miR-151,
X
1
Pleural
Pre-
2
miR-345
effusion
operative
Pre-
152
miR-25, miR-223
X
Serum
-
7
I-IIIa
8
I-IV
9
-
10
I-IV
11
I-IV
12
I-IV
13
-
14
operative
Pre114
miR-142-3p, miR-29b
X
Serum
operative
Pre-/Post-
97
miR-361-3p, miR-625
X
Serum
operative
Plasma
78
let-7f, miR-30e-3p
X
Pre-
X
vesicles
operative
Pre-
76
miR-21, miR-210, miR-486-5p
X
Plasma
operative
Pre-Post-
74
miR-155, miR-197, miR-182
X
Plasma
operative
Pre-
70
miR-21
X
X
Serum
operative
65
miR-21, miR-155, miR-182, miR-197
X
2
Serum
Pre-
3
operative
Pre63
miR-21
X
Plasma
I-IV
15
I
16
I-IV
17
I-IIIa
18
-
19
I-IV
20
I-IV
21
I-IV
22
operative
Pre58
miR-21, miR-126, miR-210, miR-486-5p
X
Plasma
operative
Pre-
55
miR-15b, miR-27b
X
Serum
operative
Pre-
52
miR-20a-5p, miR-152-3p, miR-199a-5p
X
Plasma
operative
193
miR-200b
170
miR-145, miR-451
X
Plasma
Metastases
Pre-/Post-
X
Plasma
operative
Breast cancer
Post152
miR-17, miR-34a, miR-155, miR-373
X
Serum
operative
miR-10b, miR-21, miR-145, miR-155,
Plasma/
148
Pre-/Post-
X
miR-195, miR-16, let-7a
Serum
3
operative
4
Pre132
miR-1, miR-92a, miR-133a, miR-133b
X
Serum
I-IV
23
I-IV
24
I-III
25
I-IV
26
I-IV
27
I-III
28
I-IV
29
I-IV
30
operative
Pre127
miR-148b, miR-409-3p, miR-801
X
Plasma
operative
Pre-/Post-
103
miR-155
X
Serum
operative
Pre-/Post-
102
miR-20a, miR-21, miR-214
X
Serum
operative
Pre-
102
miR-21
X
X
Serum
operative
Pre-
100
miR-92a, miR-21
X
Serum
operative
Post-
89
miR-10b, miR-34a, miR-141, miR-155
X
Serum
operative
Pre-
75
miR-215, miR-299-5P, miR-411, miR-452
X
Serum
operative
4
5
miRNA-21, miR-106a, miR-126, miR-
Pre-
68
X
Serum
155, miR-199a, miR-335
I-IIIa
31
I-III
32
I-IV
33
I-IV
34
I-IV
35
I-IV
36
Ib-IIa
37
I-IIa
38
operative
miR-10b, miR-21, miR-125b, miR-145,
Pre-
61
X
Serum
miR-155 miR-191, miR-382
operative
Pre-
60
miR-10b, miR-373
X
Plasma
operative
Pre-
96
miR-221
X
X
Serum
operative
Ovarian cancer
Pre94
miR-21
X
Serum
operative
Pre-
90
miR-218
X
Serum
operative
miR-1246, miR-20a, miR-2392, miRCervical cancer
Pre-
80
X
Serum
3147, miR-3162-5p, miR-4484
operative
Pre-
80
miR-20a, miR-203
X
Serum
operative
5
6
miR-375, miR-141, miR-378*, miR-409-
Pre-
84
X
Serum
3p
1-3
39
2a-4
40
-
41
1-4
42
-
43
2-4
44
-
45
1c-3
46
operative
Pre-
82
miR-20a, miR-21, miR-145, miR-221
X
Plasma
operative
let-7e, let-7c, miR-30c, miR-622, miR-
Pre-
80
X
Plasma
1285
operative
Various
miR-107, miR-574-3p, miR-141, miR-
Pre-/Post-
78
X
body
375, miR-200b
Prostate cancer
operative
fluids
Pre-
71
miR-375, miR-141
X
Serum
operative
Pre-
70
miR-141, miR-146b-3p, miR-194
X
Serum
operative
Pre-
51
miR-21, miR-141, miR-221
X
Plasma
operative
50
miR-141, miR375, miR-200c, miR151-3p,
X
6
Plasma
Pre-
7
miR423-3p, miR-126, miR152, miR-21,
operative
miR-16, miR-205
Pre50
miR-21
X
Serum
-
47
1-4
48
1-4
49
I-III
50
A-D
51
1-4
52
I-IV
53
operative
Pre90
miR-378, miR-451
X
Serum
operative
Renal cell
Pre84
miR-1233
X
Serum
cancer
operative
Pre-/Post68
miR-210
X
Serum
operative
Pre-
161
miR-409-3p, miR-7, miR-93
X
Plasma
operative
Colorectal
Pre157
miR-29a, miR-92a
X
Plasma
cancer
operative
miR18a, miR19a, miR19b, miR15b,
Pre-
123
X
miR29a, miR335
Plasma
operative
7
8
Pre102
miR-141
X
X
Plasma
I-IV
54
I-IV
55
I-IV
56
I-IV
57
I-IV
58
II/III
59
I-IV
60
I-IV
61
operative
Pre90
miR-601, miR-760
X
Plasma
operative
Pre-/Post-
90
miR-17-3p, miR-92
X
Plasma
operative
Pre-
70
miR-193a-3p, miR-23a, miR-338-5p
X
Blood
operative
Pre-
63
miR-34a
X
Blood
operative
Pre-
61
miRNA-29c
X
Serum
operative
miR-18a, miR-20a, miR-21, miR-29a,
Pre50
miR-92a, miR-106b, miR-133a, miR-143,
X
Plasma
operative
miR-145
Gastric cancer
164
miR-1, miR-20a, miR-27a, miR-34, miR-
X
8
Serum
Pre-
9
423-5p
operative
Pre-/Post-
90
miR-106a, miR-17
X
Blood
-
62
-
63
I-IV
64
I-IV
65
I-IV
66
I-IV
67
I-IV
68
I-IV
69
operative
Pre76
miR-196a
X
X
Serum
operative
Pre-/Post-
71
miR-17-5p, miR-20a
X
X
Plasma
operative
miR-17-5p, miR-21, miR-106a, miR-
Pre-/Post-
69
X
Plasma
106b, let-7a
operative
Pre-
69
miR-21
X
Plasma
operative
Pre-
67
miR-200c
X
X
Blood
operative
Pre-
61
miR-187, miR-371-5p, miR-378
X
Serum
operative
60
106b, miR-20a, miR-221
X
9
Plasma
Pre-
10
operative
Pre60
miR-223, miR-21, miR-218
X
Plasma
I-IV
70
-
71
Ia-IIa
72
A-D
73
A-D
74
I-IIIa
75
I-III
76
-
77
operative
Pre58
miR-221, miR-376c, miR-744
X
Serum
operative
Pre-/Post-
50
miR-199a-3p
X
Plasma
operative
miR-122, miR-192, miR-21, miR-223,
Pre-
390
X
Plasma
miR-26a, miR-27a, miR-801
operative
Pre-
195
miR-1, miR-122
X
Serum
operative
Hepatocellular
Pre-/Postcancer
126
miR-21
X
Plasma
operative
Pre-
120
miR-25, miR-375, let-7f
X
Serum
operative
105
miR-16, miR-199a
X
10
Serum
Pre-
11
operative
Pre86
miR-18a
X
Serum
I-IV
78
I-IV
79
I-IV
80
I-IV
81
I-IV
82
I-IV
83
I-IV
84
I-IV
85
operative
Pre-/Post57
miR-15b, miR-130b
X
Serum
operative
Pre-
197
miR-21
X
Serum
operative
Pancreatic
cancer
miR-16, miR-21, miR-155, miR-181a,
Pre-
140
X
Plasma
miR-181b, miR-196a, miR-210
operative
miR-10a, miR-22, miR-100, miR-148b,
Pre-
290
X
Serum
miR-223, miR-133a, miR-127-3p
operative
Pre-
Oesophageal
106
miR-18a
X
Plasma
operative
cancer
Pre101
miR-1246
X
X
Serum
operative
71
miR-21
X
11
Serum
Pre-
12
treatment
Pre64
miR-21, miR-145, miR-200c, let-7c
X
Serum
I-IV
86
-
87
I-IV
88
I-IV
89
I-IV
90
III-IV
91
II-IV
92
I-III
93
treatment
Pre60
miR-155, miR-183
X
Plasma
treatment
Pre-Post-
50
miR-21, miR-375
X
Plasma
operative
Head and neck
Pre-/Post50
miR-21
X
Plasma
cancer
operative
Pre-
Thyroid cancer
106
let-7e, miR-151-5p, miR-222
X
Serum
operative
miR-15b*, miR-23a, miR-133a, miR-150*,
Brain Tumours
Pre-
122
X
Serum
miR-197, miR-497, miR-548b-5p
operative
Pre-/Post-
94
miR-221
X
X
Serum
operative
Melanoma
80
miR-150, miR-15b, miR-199a-5p, miR-
X
12
Serum
Pre-/Post-
13
33a, miR-424
Myelodysplasia
50
let-7a, miR-16
79
miR-221
operative
X
X
Plasma
-
1-2
94
X
Plasma
-
I-IV
95
Serum
-
I-IV
96
Serum
-
I-IV
97
-
I-IV
98
miR-15a, miR-16-1, miR-29c, miR-155,
Lymphoma
75
X
miR-34a
60
miR-21
228
miR-155
X
X
Plasma/
X
Vesicles
miR-10a-5p, miR-93-5p, miR-129-5p,
Leukaemia
140
X
Serum
-
M1-M5
99
X
Plasma
-
M1-M7
100
miR-155-5p, miR-181b-5p, miR-320d
77
miR-92a, miR-638
This table is not comprehensive and is based on our review of studies with more than 50 patients. The quantification of circulating microRNAs
was carried out by quantitative real-time PCR.
13
14
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
Chen, X. et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive
biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 130, 1620-8 (2012).
Cui, E.H. et al. Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based
chemotherapy. Acta Pharmacol Sin 34, 309-13 (2013).
Hu, Z. et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of nonsmall-cell lung cancer. J Clin Oncol 28, 1721-6 (2010).
Yuxia, M., Zhennan, T. & Wei, Z. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor
prognosis. J Cancer Res Clin Oncol 138, 2045-50 (2012).
Wang, Y. et al. Pathway-Based Serum microRNA Profiling and Survival in Patients with Advanced Stage Non-Small Cell Lung Cancer.
Cancer Res 73, 4801-9 (2013).
Wang, T. et al. Cell-free microRNA expression profiles in malignant effusion associated with patient survival in non-small cell lung
cancer. PLoS One 7, e43268 (2012).
Chen, X. et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res
18, 997-1006 (2008).
Kaduthanam, S. et al. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients. Lung Cancer 80,
223-7 (2013).
Roth, C. et al. Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from
benign lung tumors. PLoS One 7, e38248 (2012).
Silva, J. et al. Vesicle-related microRNAs in plasma of NSCLC patients and correlation with survival. Eur Respir J 37, 617-23 (2011).
Shen, J. et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer
11, 374 (2011).
Zheng, D. et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 4, 575-86 (2011).
Liu, X.G. et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med
Oncol 29, 618-26 (2012).
Abd-El-Fattah, A.A., Sadik, N.A., Shaker, O.G. & Aboulftouh, M.L. Differential MicroRNAs Expression in Serum of Patients with Lung
Cancer, Pulmonary Tuberculosis, and Pneumonia. Cell Biochem Biophys 67, 875-84 (2013).
Wei, J. et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung
cancer. Chin J Cancer 30, 407-14 (2011).
Shen, J. et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 91, 579-87 (2011).
Hennessey, P.T. et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One 7, e32307 (2012).
14
15
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
Sanfiorenzo, C. et al. Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC.
PLoS One 8, e54596 (2013).
Madhavan, D. et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast
cancer. Clin Cancer Res 18, 5972-82 (2012).
Ng, E.K. et al. Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One 8, e53141 (2013).
Eichelser, C., Flesch-Janys, D., Chang-Claude, J., Pantel, K. & Schwarzenbach, H. Deregulated serum concentrations of circulating cellfree microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem 59, 1489-96
(2013).
Heneghan, H.M. et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 251, 499-505 (2010).
Chan, M. et al. Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res 19, 4477-87 (2013).
Cuk, K. et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer 132, 1602-12 (2013).
Sun, Y. et al. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One 7, e47003 (2012).
Schwarzenbach, H., Milde-Langosch, K., Steinbach, B., Muller, V. & Pantel, K. Diagnostic potential of PTEN-targeting miR-214 in the
blood of breast cancer patients. Breast Cancer Res Treat 134, 933-41 (2012).
Asaga, S. et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem 57, 84-91 (2011).
Si, H. et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer
Res Clin Oncol 139, 223-9 (2013).
Roth, C. et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res
12, R90 (2010).
van Schooneveld, E. et al. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially
expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res 14, R34 (2012).
Wang, F., Zheng, Z., Guo, J. & Ding, X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients
with breast tumor. Gynecol Oncol 119, 586-93 (2010).
Mar-Aguilar, F. et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers 34,
163-9 (2013).
Chen, W., Cai, F., Zhang, B., Barekati, Z. & Zhong, X.Y. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node
metastasis of breast cancer: potential biomarkers. Tumour Biol 34, 455-62 (2013).
Hong, F., Li, Y., Xu, Y. & Zhu, L. Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. J Int
Med Res 41, 64-71 (2013).
15
16
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
Xu, Y.Z., Xi, Q.H., Ge, W.L. & Zhang, X.Q. Identification of Serum MicroRNA-21 as a Biomarker for Early Detection and Prognosis in
Human Epithelial Ovarian Cancer. Asian Pac J Cancer Prev 14, 1057-60 (2013).
Yu, J. et al. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J Cancer Res Clin Oncol 138,
671-4 (2012).
Chen, J. et al. Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell
carcinoma. Int J Mol Med 32, 557-67 (2013).
Zhao, S., Yao, D., Chen, J. & Ding, N. Circulating miRNA-20a and miRNA-203 for Screening Lymph Node Metastasis in Early Stage
Cervical Cancer. Genet Test Mol Biomarkers 17, 631-6 (2013).
Nguyen, H.C. et al. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk,
localized prostate cancer. Prostate 73, 346-54 (2013).
Shen, J. et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 72, 1469-77 (2012).
Chen, Z.H. et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate 72, 1443-52 (2012).
Bryant, R.J. et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106, 768-74 (2012).
Brase, J.C. et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128, 608-16 (2011).
Selth, L.A. et al. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer 109, 641-50 (2013).
Yaman Agaoglu, F. et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour
Biol 32, 583-8 (2011).
Watahiki, A. et al. Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer. Int J Mol Sci
14, 7757-70 (2013).
Zhang, H.L. et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential
predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71, 326-31 (2011).
Redova, M. et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 10, 55
(2012).
Wulfken, L.M. et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 6, e25787
(2011).
Zhao, A., Li, G., Peoc'h, M., Genin, C. & Gigante, M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal
cell carcinoma. Exp Mol Pathol 94, 115-20 (2013).
Wang, S. et al. A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer (2013).
Huang, Z. et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127, 118-26
(2010).
16
17
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
Giraldez, M.D. et al. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation
study. Clin Gastroenterol Hepatol 11, 681-8 e3 (2013).
Cheng, H. et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 6,
e17745 (2011).
Wang, Q. et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One 7, e44398
(2012).
Ng, E.K. et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal
cancer screening. Gut 58, 1375-81 (2009).
Yong, F.L., Law, C.W. & Wang, C.W. Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early
detection of colorectal cancer. BMC Cancer 13, 280 (2013).
Nugent, M., Miller, N. & Kerin, M.J. Circulating miR-34a levels are reduced in colorectal cancer. J Surg Oncol 106, 947-52 (2012).
Yang, I.P. et al. The Functional Significance of MicroRNA-29c in Patients with Colorectal Cancer: A Potential Circulating Biomarker
for Predicting Early Relapse. PLoS One 8, e66842 (2013).
Luo, X., Stock, C., Burwinkel, B. & Brenner, H. Identification and evaluation of plasma MicroRNAs for early detection of colorectal
cancer. PLoS One 8, e62880 (2013).
Liu, R. et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for
gastric cancer diagnosis. Eur J Cancer 47, 784-91 (2011).
Zhou, H. et al. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J
Mol Med (Berl) 88, 709-17 (2010).
Tsai, K.W. et al. Aberrant expression of miR-196a in gastric cancers and correlation with recurrence. Genes Chromosomes Cancer 51,
394-401 (2012).
Wang, M. et al. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. Mol Med Rep 5, 1514-20 (2012).
Tsujiura, M. et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 102, 1174-9 (2010).
Komatsu, S. et al. Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. Anticancer Res 33, 271-6
(2013).
Valladares-Ayerbes, M. et al. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med 10, 186
(2012).
Liu, H. et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett
316, 196-203 (2012).
Cai, H. et al. Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Med Oncol 30, 452 (2013).
17
18
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
Li, B.S. et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One
7, e41629 (2012).
Song, M.Y. et al. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One 7,
e33608 (2012).
Li, C. et al. MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer. J Surg Oncol 108, 89-92 (2013).
Zhou, J. et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 29, 4781-8 (2011).
Koberle, V. et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J
Cancer 49, 3442-9 (2013).
Tomimaru, Y. et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 56, 167-75 (2012).
Li, L.M. et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma.
Cancer Res 70, 9798-807 (2010).
Qu, K.Z., Zhang, K., Li, H., Afdhal, N.H. & Albitar, M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin
Gastroenterol 45, 355-60 (2011).
Li, L., Guo, Z., Wang, J., Mao, Y. & Gao, Q. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma
screening. Dig Dis Sci 57, 2910-6 (2012).
Liu, A.M. et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective
cohort study. BMJ Open 2, e000825 (2012).
Liu, R. et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 58,
610-8 (2012).
Liu, J. et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 131, 683-91
(2012).
Zhang, C. et al. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 56, 1871-9
(2010).
Hirajima, S. et al. Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer
108, 1822-9 (2013).
Takeshita, N. et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal
squamous cell carcinoma. Br J Cancer 108, 644-52 (2013).
Kurashige, J. et al. Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J Surg Oncol 106,
188-92 (2012).
18
19
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
Tanaka, K. et al. Circulating miR-200c Levels Significantly Predict Response to Chemotherapy and Prognosis of Patients Undergoing
Neoadjuvant Chemotherapy for Esophageal Cancer. Ann Surg Oncol 20 Suppl 3, 607-15 (2013).
Liu, R. et al. Circulating miR-155 expression in plasma: a potential biomarker for early diagnosis of esophageal cancer in humans. J
Toxicol Environ Health A 75, 1154-62 (2012).
Komatsu, S. et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 105, 104-11
(2011).
Hsu, C.M. et al. Circulating miRNA is a novel marker for head and neck squamous cell carcinoma. Tumour Biol 33, 1933-42 (2012).
Yu, S. et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol
Metab 97, 2084-92 (2012).
Yang, C. et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential
noninvasive biomarkers for malignant astrocytomas. Int J Cancer 132, 116-27 (2013).
Kanemaru, H. et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci
61, 187-93 (2011).
Friedman, E.B. et al. Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med 10, 155 (2012).
Zuo, Z. et al. Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with
myelodysplastic syndrome. Blood 118, 413-5 (2011).
Guo, H.Q., Huang, G.L., Guo, C.C., Pu, X.X. & Lin, T.Y. Diagnostic and prognostic value of circulating miR-221 for extranodal natural
killer/T-cell lymphoma. Dis Markers 29, 251-8 (2010).
Fang, C. et al. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol 91, 553-9 (2012).
Lawrie, C.H. et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell
lymphoma. Br J Haematol 141, 672-5 (2008).
Ferrajoli, A. et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic
lymphocytic leukemia. Blood 122, 1891-9 (2013).
Zhi, F. et al. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia. PLoS One 8, e56718
(2013).
Tanaka, M. et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 4, e5532 (2009).
19